2 weeks FDA Accepts J&J’s Filing for Autoimmune Disease Drug Nipocalimab Zacks

JNJ’s filing seeks the FDA’s approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.

Johnson & Johnson (JNJ)